Genzyme ($GENZ), subject to a hostile bid by Sanofi-Aventis ($SNY), said it has satisfied a key component of a consent decree imposed by U.S. regulators after a crisis at its Boston manufacturing facility led to shortages of two key drugs. Report
Genzyme ($GENZ), subject to a hostile bid by Sanofi-Aventis ($SNY), said it has satisfied a key component of a consent decree imposed by U.S. regulators after a crisis at its Boston manufacturing facility led to shortages of two key drugs. Report